{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-26-000010","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2026-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.810945+00:00","generated_at":"2026-05-16T11:47:11.250500+00:00","sec_items":["5.03"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"IGC Pharma changes fiscal year-end from March 31 to December 31, effective 2025","bullets":["Board approved fiscal year change from March 31 to December 31, effective Dec 31, 2025.","Company will file a Transition Report on Form 10-K for the nine-month period April 1 to Dec 31, 2025.","Future fiscal years will end on December 31, aligning with the calendar year."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-000010","json":"https://secwatch.observer/filing/0001185185-26-000010.json","markdown":"https://secwatch.observer/filing/0001185185-26-000010.md","text":"https://secwatch.observer/filing/0001185185-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/igc8k010226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:47:11.250500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aff8432607a99073361bcfebc78df70aea9fa910","claim":"IGC Pharma, Inc.: Changed fiscal year-end from March 31 to December 31 (effective 2025-12-31).","evidence_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001178253-26-000017","ticker":"SCYX","company_name":"SCYNEXIS INC","filed_at":"2026-05-29T20:01:37+00:00","headline":"SCYNEXIS effects 1:8 reverse stock split; authorized shares cut to 18.75M","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178253-26-000017","json":"https://secwatch.observer/filing/0001178253-26-000017.json","markdown":"https://secwatch.observer/filing/0001178253-26-000017.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/0001178253-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/scyx-20260528.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"On May 28, 2026, SCYNEXIS, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), to effect a one-for-eight (1:8) reverse stock split of its outstanding common stock (the “Reverse Stock Split”) and a reduction in the total number of authorized shares of its common stock from 150,000,000 to 18,750,000, effective as of May 29, 2026 (the “Share Reduction”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/0001178253-26-000017-index.htm"}},{"accession":"0001213900-26-062184","ticker":"RLMD","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2026-05-28T20:59:47+00:00","headline":"Relmada increases authorized common shares to 200M; stockholders approve 2021 Plan amendment","event_type":"other","sec_items":["5.03","5.07","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062184","json":"https://secwatch.observer/filing/0001213900-26-062184.json","markdown":"https://secwatch.observer/filing/0001213900-26-062184.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/0001213900-26-062184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/ea0292521-8k_relmada.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “ Charter Amendment ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/0001213900-26-062184-index.htm"}},{"accession":"0001551306-26-000109","ticker":"PGNY","company_name":"Progyny, Inc.","filed_at":"2026-05-27T13:13:46+00:00","headline":"Progyny shareholders approve elimination of supermajority voting requirements","event_type":"other","sec_items":["5.03","5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001551306-26-000109","json":"https://secwatch.observer/filing/0001551306-26-000109.json","markdown":"https://secwatch.observer/filing/0001551306-26-000109.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551306/000155130626000109/0001551306-26-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551306/000155130626000109/pgny-20260521.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"Progyny, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the Company’s stockholders approved certain amendments (the “Charter Amendments”) to the Company’s Certificate of Incorporation. As further described in Proposals 4 and 5 of the Company’s definitive proxy statement filed on April 10, 2026 (the “Proxy Statement”), the Charter Amendments (a) eliminate certain supermajority voting requirements (the “Supermajority Amendments”), and (b) eliminate the default supermajority voting requirement concerning certain business combinations. The Charter Amendments became effective upon the filing of a Certificate of Amendment (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on May 21, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1551306/000155130626000109/0001551306-26-000109-index.htm"}},{"accession":"0001193125-26-232817","ticker":"T","company_name":"AT&T INC.","filed_at":"2026-05-20T21:05:35+00:00","headline":"AT&T annual meeting elects directors, approves incentive and exculpation amendment","event_type":"other","sec_items":["5.02","5.07","5.03","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-232817","json":"https://secwatch.observer/filing/0001193125-26-232817.json","markdown":"https://secwatch.observer/filing/0001193125-26-232817.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/732717/000119312526232817/0001193125-26-232817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/732717/000119312526232817/d227921d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"On May 15, 2026, the Company filed a Certificate of Amendment with the Secretary of State of Delaware to effect the Exculpation Amendment.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/732717/000119312526232817/0001193125-26-232817-index.htm"}},{"accession":"0001193125-26-251689","ticker":"SCHW","company_name":"SCHWAB CHARLES CORP","filed_at":"2026-06-01T21:00:25+00:00","headline":"Charles Schwab files Certificate of Elimination for Series I Preferred Stock","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251689","json":"https://secwatch.observer/filing/0001193125-26-251689.json","markdown":"https://secwatch.observer/filing/0001193125-26-251689.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/0001193125-26-251689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/d143555d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"On June 1, 2026, The Charles Schwab Corporation (the “Company”) filed a Certificate of Elimination with the Secretary of State of the State of Delaware with respect to the Company’s 4.000% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series I (“Series I Preferred Stock”), which, effective upon filing, eliminated from the Company’s Fifth Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations for the Series I Preferred Stock.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/0001193125-26-251689-index.htm"}},{"accession":"0001395942-26-000022","ticker":"OPLN","company_name":"OPENLANE, Inc.","filed_at":"2026-05-29T17:57:10+00:00","headline":"OPENLANE eliminates Series A Convertible Preferred Stock from charter","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001395942-26-000022","json":"https://secwatch.observer/filing/0001395942-26-000022.json","markdown":"https://secwatch.observer/filing/0001395942-26-000022.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395942/000139594226000022/0001395942-26-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395942/000139594226000022/kar-20260529.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"On May 29, 2026, OPENLANE, Inc. (the “Company”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware effecting the elimination of the Certificate of Designations relating to the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”) previously filed by the Company with the Secretary of State of the State of Delaware on June 9, 2020.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1395942/000139594226000022/0001395942-26-000022-index.htm"}},{"accession":"0000014707-26-000070","ticker":"CAL","company_name":"CALERES INC","filed_at":"2026-05-28T21:22:24+00:00","headline":"Caleres reduces board size from 11 to 10; shareholders re-elect all directors and approve compensation plan","event_type":"other","sec_items":["5.03","5.07","9.01"],"materiality_score":0.1,"calibrated_materiality_score":0.1,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0000014707-26-000070","json":"https://secwatch.observer/filing/0000014707-26-000070.json","markdown":"https://secwatch.observer/filing/0000014707-26-000070.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/14707/000001470726000070/0000014707-26-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14707/000001470726000070/cal-20260528x8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"On May 28, 2026, the Board of Directors amended Article II, Section 1 of the Company’s Bylaws to decrease the number of directors from eleven to ten, effective May 28, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/14707/000001470726000070/0000014707-26-000070-index.htm"}},{"accession":"0001437749-26-018579","ticker":"SLE","company_name":"Super League Enterprise, Inc.","filed_at":"2026-05-27T20:31:43+00:00","headline":"Super League Enterprise cancels Series AA Preferred Stock designation","event_type":"other","sec_items":["3.03","5.03","9.01"],"materiality_score":0.05,"calibrated_materiality_score":0.05,"match_reasons":["same fact type: governance_change","same SEC item: 5.03","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018579","json":"https://secwatch.observer/filing/0001437749-26-018579.json","markdown":"https://secwatch.observer/filing/0001437749-26-018579.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621672/000143774926018579/0001437749-26-018579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621672/000143774926018579/slgg20260527_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm","comparable_excerpt":"On May 22, 2026 (the “ Effective Date ”), Super League Enterprise, Inc. (the “ Company ”) filed a Cancellation of Certificate of Designation with the Secretary of State of the State of Delaware to terminate the designation of its Series AA Preferred Stock (the “ Certificate of Cancellation ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1621672/000143774926018579/0001437749-26-018579-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}